{'fraction_non_alphanumeric': 0.028288543140028287, 'fraction_numerical': 0.009900990099009901, 'mean_word_length': 6.375, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
T‐cell immunoglobulin mucin‐3 expression in bladder urothelial carcinoma: Clinicopathologic correlations and association with survival

T cell immunoglobulin mucin‐3 (Tim‐3) was initially recognized as a pivotal immune checkpoint inhibitor that maintains immune homeostasis and tolerance. Recently, Tim‐3 has been demonstrated to play an important role in tumor‐associated immune suppression and aberrant Tim‐3 expression has been reported in several human malignancies. However, the role of Tim‐3 in bladder urothelial carcinoma (BUC) remains largely unknown. The present study aims to investigate Tim‐3 expression in BUC and analyze correlations with clinicopathologic outcomes and postoperative survival.